The Impact of Banning Electronic Nicotine Delivery Systems on Combustible Cigarette Sales: Evidence From US State-Level Policies.

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

In the fall of 2019, several states in the United States passed emergency bans on the sale of electronic nicotine delivery systems (ENDS), in response to an outbreak of illnesses strongly linked to tetrahydrocannabinol vaping products that received national news coverage.

Given that ENDS are potential alternative nicotine products for adult smokers, banning ENDS may have unintended consequences.

This study provides evidence of an association between state-level ENDS bans and cigarette sales.

Who Took Part

The age groups tagged for this paper are adults.

The researchers used difference-in-differences and generalized synthetic control methods to estimate the impacts of the emergency ENDS bans on cigarette sales by comparing treatment states that passed ENDS bans in fall 2019 (Massachusetts, Washington, and Rhode Island), halted states that revoked the announced ENDS bans, and control states.

How the Study Was Run

In design terms this was a randomized study.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

What Was Measured

The subject headings attached to it are Commerce, Electronic Nicotine Delivery Systems, Nicotine, Policy, Tobacco Products and United States.

Author keywords: cigarette sales, difference-in-differences method, generalized synthetic control and market bans.

What This Means in Plain Language

The paper is a randomized study of Therapeutic nicotine (patch, non-peptide).

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.